NCT00424788

A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Biogen · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

Natalizumab (TYSABRI) is a protein-based drug that is manufactured by Biogen Idec in partnership with Elan Pharmaceuticals. Natalizumab is approved in the US and Europe for the treatment of Multiple Sclerosis (MS). The purpose of this study is to determine whether the amount of natalizumab (TYSABRI) that is present in your blood (plasma) can be reduced or eliminated by separating and removing the plasma and replacing it with other fluids, a process called plasma exchange.

Conditions

• Relapsing Forms of Multiple Sclerosis

Interventions

Type	Name	Description
PROCEDURE	Plasma exchange
DRUG	natalizumab treatment

Timeline

• Start date: 2007-01-01
• Primary completion: 2007-10-01
• Completion: 2007-10-01
• First posted: 2007-01-22
• Last updated: 2009-09-04

Locations

2 sites across 1 country: United States